-
Signature
-
/s/ Brian Baranick by Mark Busch, attorney-in-fact
-
Stock symbol
-
EXAS
-
Transactions as of
-
Nov 4, 2025
-
Transactions value $
-
-$200,289
-
Form type
-
4
-
Date filed
-
11/6/2025, 05:29 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Baranick Brian |
EVP, GM, Precision Oncology |
C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON |
/s/ Brian Baranick by Mark Busch, attorney-in-fact |
2025-11-06 |
0001941313 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
EXAS |
Common Stock |
Sale |
-$200K |
-2.86K |
-11.33% |
$70.08 |
22.4K |
Nov 4, 2025 |
Direct |
F1, F2 |
| holding |
EXAS |
Common Stock |
|
|
|
|
|
670 |
Nov 4, 2025 |
Held in 401(k) Plan |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: